Pancreatic cancer (PC) is highly resistant to current therapies; thus, there is an urgent need to develop new treatment strategies. The proteasome is crucially important for proteostasis, which is involved in cell proliferation and survival, making it an attractive therapeutic target in cancer. However, recent studies have indicated that bortezomib, a highly selective proteasome inhibitor, has limited effects in solid tumors including PC. Thus, more mechanistic insights into chemo-sensitization strategies for bortezomib are urgently needed. Herein, we demonstrate that bortezomib induced apoptosis and autophagy via a mechanism involving endoplasmic reticulum (ER) stress in PC cells. Additionally, bortezomib treatment led to increased levels of intracellular reactive oxygen species (ROS), which play critical roles in bortezomib-induced ER stress and apoptosis. Moreover, autophagy functions as a compensatory mechanism to eliminate bortezomib-induced ROS and resists ER stress-mediated apoptosis. Additionally, the Nrf2-mediated antioxidative response, which works against with bortezomib-induced autophagy, also protected cells against bortezomib-induced ROS production. Finally, the dual inhibition of autophagy and Nrf2 signaling cooperatively enhanced bortezomib-induced apoptosis by elevating ROS levels and ER stress. Together, these data demonstrate that activation of autophagy and the Nrf2 antioxidant system, which lowers intracellular ROS, are mechanistically how PC cells overcome bortezomib treatment. In summary, combining proteasome inhibitors with drugs targeting autophagy and Nrf2 signaling could be a promising therapeutic approach for PC treatment.
Introduction
Pancreatic cancer (PC) is among the most lethal malignant tumors; despite advances in early diagnosis and treatment, its 5-year survival rate is less than 5% and the median survival is only 6 months [1] . Surgical resection is the only potentially curative treatment but is only appropriate for a minority of patients, as most present with metastatic disease. Unfortunately, approved therapeutic approaches such as radiotherapy and chemotherapy have a relatively modest impact on survival, extending survival by an average of 1-3 months [2] . Thus, there is a continuing need to develop novel therapeutic strategies for PC.
The 26S proteasome-mediated degradation of intracellular proteins is highly regulated in eukaryotic cells. Numerous data suggest that the proteasome
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International Publisher mediates the degradation of proteins involved in cancer cell proliferation, survival and apoptosis, making it an attractive therapeutic target [3] . Bortezomib, a highly selective and potent proteasome inhibitor with broad anti-tumor activities, is actively being investigated as a potential chemotherapeutic agent [4] . It has been reported that the antitumor activity of bortezomib is achieved by affecting various signaling cascades, including the NF-κB, mitogen-activated protein kinases (MAPKs), and apoptotic pathways [5] . Based upon highly favorable results in patients with refractory or relapsed multiple myeloma, bortezomib was approved by the United States Food and Drug Administration [6] . However, recent studies have indicated that single-agent bortezomib has somewhat limited effects in solid tumors including PC, probably due to chemo-resistance or other unknown mechanisms [7, 8] .
Thus, more mechanistic insights into chemo-sensitization strategies for bortezomib are urgently needed.
The endoplasmic reticulum (ER) is an organelle that plays important roles in maintaining intracellular calcium homeostasis, protein metabolism and posttranslational modifications. An alteration in calcium homeostasis and/or accumulation of misfolded proteins in the ER results in cellular stress that causes a specialized response known as the unfolded protein response (UPR), which is the major protective and compensatory mechanism for ER stress [9, 10] . However, if the stress is too severe or persistent, the same system will trigger cell death by inducing pro-apoptotic factors such as C/EBP homologous protein (CHOP) [11] . In most cases, misfolded proteins produced by ER stress are exported to the cytoplasm and degraded by the ER-associated ubiquitin-proteasome degradation (ERAD) system [12] . Nevertheless, if the amount of misfolded proteins exceeds the capacity of the ERAD system, autophagy can compensate for protein degradation and allow cell survival [13] .
Autophagy is a lysosomal degradation pathway that eliminates damaged organelles, recycles materials and protein aggregates. Like apoptosis, autophagy is an evolutionarily conserved process that regulates cell fate in response to various stresses [14] . Besides its cytoprotective function, autophagy can also contribute to cell death. However, whether autophagy serves a protective or detrimental role varies depending on cell type and context [15] . Recently, a variety of chemotherapy agents, including bortezomib, were reported to activate autophagy in PC, suggesting that blocking autophagy could enhance its therapeutic efficacy [16, 17] . Thus, a treatment approach combining autophagy inhibition and may reverse the chemo-resistance in PC.
Reactive oxygen species (ROS) production is one of the most important antitumor mechanisms shared by all non-surgical therapeutic approaches, including chemotherapy and radiotherapy [18, 19] . Recent studies have found that a consequence of ER stress is the accumulation of ROS, which promotes oxidative stress [20] . Furthermore, several reports have shown that ROS can induce autophagy in response to chemotherapy-induced stress [21, 22] . In addition to the induction of autophagy, oxidative stress also activates the NF-E2-related factor 2 (Nrf2) pathway. Nrf2 is a critical regulator of intracellular antioxidants and detoxification enzymes that induces antioxidant response element (ARE)-driven genes expression, such as heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1) [23, 24] . Additionally, aberrant Nrf2 overexpression has been observed in several human cancers, and constitutive Nrf2 activation protects cancer cells against oxidative stress and contributes to the chemo-resistance [25, 26] . However, the molecular link between ROS, ER stress, Nrf2, and autophagy and how these pathways influence therapeutic outcomes in PC remain largely undefined. In this study, we show a novel mechanism of bortezomib resistance and an effective treatment combination to overcome bortezomib resistance.
Results

Bortezomib inhibits growth and induces apoptosis in PC cells.
To evaluate the effect of bortezomib on the growth of PC cells, MIAPaCa-2 and AsPC-1 cells were treated with increasing concentrations of bortezomib (1-500 nM) for 24 or 48 h, and then the Cell Counting Kit-8 (CCK-8) assay was performed. As indicated in Fig. 1A , cell growth was inhibited by bortezomib in a dose-and time-dependent manner. Additionally, analyzing long-term survival with colony-formation assays further confirmed that bortezomib inhibited the proliferation of both MIAPaCa-2 and AsPC-1 cells in a dose-dependent manner (Fig. 1B) .
To investigate whether the inhibitory effects of bortezomib on PC cells were due to the induction of apoptosis, MIAPaCa-2 and AsPC-1 cells were treated with bortezomib at different concentrations for 24 h, and then the cells were analyzed by Annexin V-FITC/PI staining by flow cytometry. As shown in Fig. 1C , bortezomib treatment increased the percentage of apoptotic MIAPaCa-2 and AsPC-1 cells in a dose-dependent manner. These results indicate that bortezomib inhibits growth and induces apoptosis in PC cells.
Bortezomib activates caspase cascades and the mitochondrial apoptosis pathway in PC cells.
The mitochondrial apoptosis pathway is one of the critical apoptotic pathways. Depletion of the mitochondrial membrane potential (Δψm) in response to various stimuli results in the initiation of apoptotic cascades [27, 28] . Therefore, we first investigated if bortezomib-induced apoptosis was associated with the destruction of mitochondrial homeostasis. As indicated in Fig. 1D , bortezomib treatment resulted in a dose-dependent loss of Δψm in MIAPaCa-2 and AsPC-1 cells. Additionally, we examined the activation of different caspases and the expression of a Figure 1 . Bortezomib inhibits growth and activates the mitochondrial apoptosis pathway in PC cells. (A) MIAPaCa-2 and AsPC-1 cells were treated with increasing concentrations of bortezomib (1-500 nM) for 24 or 48 h, viable cells were quantified using the CCK-8 assay. Each data point represents means ± SD of three separate experiments. (B) MIAPaCa-2 and AsPC-1 cells were incubated with the indicated concentrations of bortezomib for 24 h and allowed to grow into colonies for 14 d. Colony-formation assay was performed to determine the cytotoxic effect of bortezomib. Each bar represents means ± SD of three separate experiments. *p < 0.05; **p < 0.01; ***p < 0.001. (C) Apoptotic cells were determined by flow cytometry using annexin V/PI double staining after cells were treated with the indicated concentrations of bortezomib for 24 h. Each bar represents means ± SD of three separate experiments. *p < 0.05; **p < 0.01; ***p < 0.001. (D) MIAPaCa-2 and AsPC-1 cells were treated as described in (C), and the mitochondrial membrane potential (MMP, Δψm) was determined by JC-1 staining and analyzed by flow cytometry. Each bar represents means ± SD of three separate experiments. *p < 0.05; **p < 0.01; ***p < 0.001. (E) Western blot analysis of PARP, caspase 9, cleaved caspase-3 and Bcl-2 family proteins levels after cells were treated as described in (C). GAPDH was used as a loading control. (F) Western blot analysis of cytochrome c release from mitochondria after cells were treated as described in (C). GAPDH was used as cytosolic internal control. The band intensity was quantified by volume densitometry and normalized to that of GAPDH. (G) MIAPaCa-2 and AsPC-1 cells were treated with bortezomib (100 nM) for 24 h in the presence or absence of CsA (5 μM). Apoptotic cells were detected by flow cytometry using annexin V/PI double staining. Each bar represents means ± SD of three separate experiments. *p < 0.05. series of Bcl-2 family proteins that play pivotal roles in regulating mitochondrial apoptosis. These results showed that bortezomib dose-dependently induced cleavage of caspase-9, caspase-3 and PARP, and decreased the levels of the anti-apoptotic Bcl-2 family proteins Bcl-2, XIAP, and Bcl-XL in MIAPaCa-2 and AsPC-1 cells (Fig. 1E) . Interestingly, pretreating cells with z-VAD-FMK (a pan-caspase inhibitor) significantly attenuated bortezomib-induced cell death (Fig. S1) , suggesting that bortezomib-mediated PC cell apoptosis was caspase dependent.
By definition, dissipation of the Δψm induces the release of apoptogenic factors such as cytochrome c from mitochondria to the cytosol [28] . Consistent with this result, bortezomib treatment increased mitochondrial cytochrome c release (Fig. 1F) ; however, when cells were pre-treated with CsA (a Δψm stabilizer), bortezomib-induced cell death was partially blocked (Fig. 1G) . These results indicate that bortezomib induces apoptosis by activating a mitochondrial apoptotic pathway.
Bortezomib induces autophagic flux in PC cells.
As it is well established that proteasome inhibitors also induce autophagy in various cell types [29] , we next investigated whether bortezomib induced autophagy in PC cells. First, we monitored autophagic alterations by analyzing the conversion of cytosolic light chain 3B-I (LC3B-I) into LC3B-II. Generally, the covalent conjugation of a soluble form of LC3B (LC3B-I) with phosphatidylethanolamine, forming the insoluble LC3B-II, correlates with the extent of autophagy [14] . As shown in Fig. 2A , bortezomib treatment of MIAPaCa-2 and AsPC-1 cells induced a dose-dependent increase in LC3B-II expression. To further monitor autophagosome formation, a lentivirus vector encoding GFP-LC3B fusion protein was used. As expected, bortezomib treatment increased GFP-LC3B puncta in both MIAPaCa-2 and AsPC-1 cells, indicating that there was a cumulative increase in autophagosomes (Fig.  2B) . Moreover, ultra-structural analyses by transmission electron microscopy (TEM) revealed increased autophagosome numbers in the cytoplasm of bortezomib-exposed MIAPaCa-2 and AsPC-1 cells (Fig. 2C) . We next examined the effects of bortezomib on the expression of several critical autophagy-related proteins. Paradoxically, Beclin1 expression was markedly decreased in bortezomib-treated MIAPaCa-2 cells, whereas no apparent changes were detected in Atg5 or Atg7 expression (Fig. S2) .
As both autophagy induction and impaired autophagic degradation have been ascribed to autophagosome accumulation in cells [30] , the effect of inhibiting the lysosomal turnover of autophagosome contents by the lysosome inhibitor chloroquine (CQ) was examined. As indicated in Fig.  2D , CQ treatment dramatically increased bortezomibinduced LC3B-II accumulation in both MIAPaCa-2 and AsPC-1 cells, suggesting bortezomib induced autophagy activation. To further confirm that bortezomib induces autophagic flux, a tandem GFP-mRFP-LC3B lentivirus construct was used. This probe can be used to identify autophagosomes (GFP positive/RFP positive; yellow dots) and autolysosomes (GFP-negative/RFP-positive; red dots), because GFP fluorescence is sensitive to pH and quenched in the acidic lysosomal environment, whereas mRFP is resistant [30] . As shown in Fig. 2E , CQ inhibited autophagosome maturation, resulting in the accumulation of yellow puncta without any significant increase in the number of red puncta in MIAPaCa-2 cells. Conversely, in bortezomib-treated cells, only parts of the LC3B-positive puncta were yellow, indicating increased autophagic flux. Similar results were found using AsPC-1 cells (Fig. S3) .
Collectively, these data demonstrate that bortezomib induces autophagic flux in PC cells.
Bortezomib-induced apoptosis and autophagy are associated with ER stress.
It has been hypothesized that proteasome inhibition may prevent the clearance of misfolded proteins by the ERAD pathway, resulting in ER stress [31] . As expected, the level of ubiquitinated proteins in MIAPaCa-2 and AsPC-1 cells were dosedependently increased after bortezomib treatment ( Fig.  3A) , suggesting bortezomib inhibited proteasome activity. To verify whether ER stress was a consequence of bortezomib-induced proteasome inhibition, cells were stained with the ER-specific marker calnexin. In untreated cells, the ER had a reticular pattern, whereas following bortezomib treatment, numerous cytoplasmic vacuoles appeared (Fig. 3B) . Furthermore, bortezomib dose-dependently increased expression of the ER stress-associated proteins Bip and CHOP (Fig. 3C) , JNK activation ( Fig.  3C ) and intracellular calcium levels ( Fig. 3D) , which are also important markers of ER stress [11] , indicating ER stress in bortezomib-treated PC cells.
Emerging evidence has indicated that ER stress is a potent trigger of autophagy [13, 32] ; moreover, CHOP is generally considered a pro-apoptotic factor during ER stress that regularly participates in ER stress-mediated autophagy [33, 34] . Therefore, to further establish the functional role of ER stress in bortezomib-induced PC cell autophagy, CHOPspecific siRNA was used. As shown in Fig. 3E , CHOP-specific siRNA effectively silenced CHOP at the protein level and attenuated bortezomib-induced LC3B-II formation in both MIAPaCa-2 and AsPC-1 cells. Additionally, CHOP knockdown markedly reduced bortezomib-induced apoptosis compared with control siRNA (Fig. 3E) . Similarly, the ER stress inhibitor TUDCA significantly decreased bortezomibinduced Bip and CHOP expression, attenuated LC3B-II formation and decreased bortezomib-induced apoptosis (Fig. 3F) . Conversely, the addition of a typical ER stress inducer, TM, with bortezomib significantly increased LC3B-II formation and the apoptotic ratio compared with either agent alone (Fig.  3F) .
Previous studies have reported that releasing calcium from the ER into the cytosol and mitochondria promotes apoptosis due to mitochondrial calcium overload [35] . To determine whether increased intracellular calcium is important for bortezomib-induced PC cell apoptosis, we first detected changes in subcellular calcium accumulation by Immunofluorescence. Interestingly, confocal microscopy indicated that bortezomib treatment induced a remarkable increase in cytosolic calcium colocalized within mitochondria in MIAPaCa-2 and AsPC-1 cells (Fig. 3G) . Additionally, inhibiting calcium accumulation with BAPTA-AM (an MIAPaCa-2 cells transfected with GFP-mRFP-LC3B were treated with DMSO (<0.1%), CQ (10 μM), or bortezomib (100 nM) for 24 h, and then observed for the change of both green and red fluorescence using a confocal microscope. Scale bar: 20 μm. The numbers of acidified autophagosomes (GFP -/RFP + ) versus neutral autophagosomes (GFP + /RFP + ) per cell in each condition were quantified. Data are presented as mean ± SD from three separate experiments. N.S, not significant; *p < 0.05; ***p < 0.001. intracellular calcium chelator) pretreatment significantly suppressed the bortezomib-induced loss of Δψm and activation of apoptosis ( Fig. 3H and I) . Taken together, these results indicate that bortezomib triggered ER stress, which subsequently induced apoptosis and autophagy in PC cells.
Autophagy protects against bortezomib-induced apoptosis in PC cells.
Having clearly established that bortezomib activates autophagy in PC cells, we next sought to determine how autophagy contributes to cell death.
To explore the biological role of autophagy in bortezomib-induced cell death, CQ was used to block lysosomal function and prevent complete autophagy. As shown in Fig. 4A , both MIAPaCa-2 and AsPC-1 cells had more significantly inhibited growth after combined bortezomib and CQ treatment compared with bortezomib alone. Furthermore, CQ markedly increased bortezomib-induced caspase-3 and PARP cleavage (Fig. 4B) . To exclude non-specific CQ effects, we silenced Atg5, an essential autophagy gene, via siRNA and analyzed the relationship between apoptosis and autophagy. Downregulating Atg5, Western blot analysis of ER stress-related protein levels after MIAPaCa-2 and AsPC-1 cells were treated as described in (A). (D) MIAPaCa-2 and AsPC-1 cells were treated as described in (A), and the cytosolic calcium levels was determined by Fluo-3/AM staining and analyzed by flow cytometry. Each bar represents means ± SD of three separate experiments. *p < 0.05; **p < 0.01; ***p < 0.001. (E) MIAPaCa-2 and AsPC-1 cells were transfected with CHOP siRNAs for 48 h and then cells were treated with the indicated concentrations of bortezomib for an additional 24 h. The indicated protein levels (upper panel) and the apoptotic cells (lower panel) were determined by western blot and annexin V/PI double staining assay, respectively. Each bar represents means ± SD of three separate experiments. *p < 0.05. (F) MIAPaCa-2 cells were pretreated with TUDCA (1 mM) or TM (10 μg/ml) for 30 min, and then exposed to bortezomib (100 nM) for 24 h. The indicated protein levels (upper panel) and the apoptotic cells (lower panel) were determined by western blot and annexin V/PI double staining assay, respectively. Each bar represents means ± SD of three separate experiments. *p < 0.05; **p < 0.01. (G) MIAPaCa-2 and AsPC-1 cells were treated with DMSO (<0.1%) or bortezomib (100 nM) for 24 h. After incubated with MitoTracker Red for 30 min, cells were stained with Fluo-3/AM and observed under a confocal microscope. Scale bar: 10 μm. (H, I) MIAPaCa-2 and AsPC-1 cells were treated with bortezomib (100 nM) for 24 h in the presence or absence of BAPTA-AM (10 μM). The Δψm (H) and the apoptotic cells (I) were detected by flow cytometry using JC-1 and annexin V/PI double staining assay, respectively. Each bar represents means ± SD of three separate experiments. *p < 0.05.
which significantly decreased LC3B-II accumulation in bortezomib-treated cells, enhanced the sensitivity to bortezomib-induced cell death and increased cleaved caspase-3 and PARP levels ( Fig. 4C-E) . Interestingly, inhibiting autophagy by silencing Atg5 also resulted in a significant increase in bortezomib-induced Bip and CHOP expression in MIAPaCa-2 and AsPC-1 cells (Fig. 4E) .
Beclin1 is a key initiator of autophagy in mammalian cells [14] ; thus, the finding that bortezomib treatment did not stimulate increased Beclin1 expression prompted us to investigate the role of Beclin1 in bortezomib-induced autophagy. Surprisingly, silencing Beclin1 via Beclin1 siRNA did not affect the accumulation of LCB3-II in bortezomib-treated cells, nor show any significant effect on bortezomib-induced apoptosis (Fig. S4) . Collectively, these data indicated that bortezomib induced protective autophagy in PC cells via a Beclin1-independent pathway, which alleviates ER stress and reduces apoptosis.
ROS elevation is a critical event in bortezomib-induced ER stress and autophagy in PC cells.
ER stress, autophagy and oxidative stress are closely linked events. Bortezomib reportedly induces ROS generation in cancer cells [36, 37] . Therefore, to gain further insight into the mechanism of bortezomib-induced ER stress and autophagy in PC cells, we assessed intracellular ROS levels using the fluorescent probe DCFH-DA. There was a significant increase in intracellular ROS levels in MIAPaCa-2 and AsPC-1 cells following bortezomib treatment (Fig.  5A) . This increase in bortezomib-induced ROS could be blocked by pretreating cells with the ROS scavenger, NAC (Fig. 5B) . Moreover, NAC also significantly attenuated bortezomib-induced apoptosis and decreased cleaved caspase-3 and PARP levels ( Fig. 5C and D) . We then focused our attention onto whether ROS generation was associated with bortezomib-induced ER stress and autophagy. As expected, pretreating cells with NAC not only attenuated bortezomib-induced increased intracellular calcium levels (Fig. S5) , but also decreased bortezomib-induced Bip and CHOP expression (Fig. 5D) . Furthermore, NAC significantly decreased LC3B-II accumulation (Fig. 5D) . These results indicated that ROS generation plays a critical role in bortezomib-induced ER stress and autophagy in PC cells.
Autophagy and Nrf2 signaling are adaptive mechanisms for bortezomib-induced ROS production.
It has been proposed that augmented autophagic removal of oxidatively damaged organelles and proteins is a defense against oxidative stress [38] . To determine whether autophagy could modulate bortezomib-induced ROS production in PC cells, we quantified intracellular ROS levels after combined treatment with bortezomib and CQ. As shown in Fig.  6A , ROS levels were markedly increased in MIAPaCa-2 and AsPC-1 cells treated with the combination of bortezomib and CQ compared with bortezomib alone. Similarly, inhibiting autophagy by silencing Atg5 enhanced bortezomib-induced ROS levels (Fig. 6B) .
The transcription factor Nrf2 is the main adaptive cellular regulator that protects against oxidative stress [23, 24] . We next investigated whether Nrf2 was involved in bortezomib-induced ROS production in PC cells. As shown in Fig. 6C , levels of Nrf2 and its downstream targets HO-1 and NQO1 increased following bortezomib treatment in MIAPaCa-2 and AsPC-1 cells. Moreover, levels of Nrf2 in the nuclear fraction were also dramatically stimulated after bortezomib treatment, indicating the nuclear translocation of Nrf2, where it stimulated the transcription of its target genes. Additionally, Nrf2 knockdown via siRNA resulted in a slightly increased basal ROS levels, which were further elevated compared with scrambled siRNA-transfected cells following bortezomib treatment, indicating that the Nrf2 pathway participated in bortezomib-induced ROS generation (Fig. 6D) . Intriguingly, in cells where Nrf2 was downregulated, both basal and bortezomibinduced LC3B-II formation were also elevated (Fig.  6E) , indicating the compensatory role of autophagy under increased ROS conditions. Consistent with these results, we found a significant increase in GFP-LC3B puncta in the cytoplasm of cells transfected with Nrf2 siRNA compared with scrambled siRNA upon bortezomib exposure (Fig. S6) . Together, these findings indicate that both autophagy and Nrf2 signaling are adaptive mechanisms that are activated upon bortezomib-induced ROS generation in PC cells.
Combined inhibition of autophagy and Nrf2 pathway augments bortezomib-induced apoptosis in PC cells.
Given that our previous experiments showed that bortezomib increased intracellular ROS levels, which then induced autophagy and Nrf2 pathway activation, we next queried whether the dual activation of autophagy and the Nrf2 antioxidant system caused a potent cooperative effect to counteract bortezomib in PC cells. As shown in Fig.  7A and B, compared with individually knocking down Atg5 or Nrf2, combined Atg5 and Nrf2 knockdown further augmented bortezomib-induced ROS levels and apoptosis rates in MIAPaCa-2 and AsPC-1 cells. More remarkably, double Atg5 and Nrf2 knockdown cooperatively enhanced bortezomibinduced Bip and CHOP expression as well as caspase-9, caspase-3 and PARP cleavage compared with single Atg5 or Nrf2 knockdown (Fig. 7C and Fig.  S7 ), indicating that simultaneously suppressing autophagy and the Nrf2 pathway enhances Bortezomib-induced ER stress and apoptosis at least in an additive manner in PC cells. Of note, Atg5-specific siRNA caused a marked increase in bortezomib-induced Nrf2 expression compared with scrambled siRNA-transfected cells (Fig. 7C and Fig.  S7 ), suggesting that suppressing autophagy increases the cell's reliance on the Nrf2 pathway during bortezomib treatment. Conversely, pretreating cells with NAC or TUDCA strikingly attenuated the cell death induced by combination treatment (Fig. 7D) , indicating that both ER stress and ROS play a key role in the cytotoxicity of the combination treatment. From these results, we conclude that combined inhibition of autophagy and Nrf2 pathway rendered PC cells vulnerable to bortezomib by increasing ROS production and ER stress.
Discussion
Herein, we report that treating PC cells with bortezomib triggers ER stress and subsequently induce autophagy and apoptosis. Bortezomib also increased intracellular ROS, which plays a critical role in bortezomib-induced ER stress and apoptosis. Moreover, autophagy activation functions as a compensatory mechanism to eliminate bortezomibinduced ROS and resist ER stress-mediated apoptosis. Additionally, Nrf2-mediated antioxidative responses, which negatively impact bortezomib-induced autophagy, also protect against bortezomib-induced ROS production. Finally, we found that the combined inhibition of autophagy and Nrf2 signaling resulted in an additive enhancement of bortezomib-induced apoptosis by promoting ROS accumulation and ER stress in PC cells.
Proteasome inhibition appears to prevent the clearance of misfolded proteins through the ERAD system, which leads to protein aggregation in the ER, triggering ER stress-mediated apoptosis. Indeed, it has been widely reported that ER stress is involved in the antitumor effects of proteasome inhibitors [6, 8] . Consistent with previous studies, our results indicated that bortezomib treatment increased the levels of both ubiquitinated proteins and ER stress-associated proteins in PC cells. Moreover, bortezomib increased JNK activation and intracellular calcium levels, both of which are indicative of ER stress [11] . These findings suggest that bortezomib induces ER stress in PC cells. CHOP is a crucial mediator of apoptosis following ER stress [11] . We found that downregulating CHOP via siRNA blocked bortezomib-induced apoptosis. Furthermore, pretreatment with the ER stress inhibitor TUDCA dramatically attenuated bortezomib-induced apoptosis; whereas the addition of a typical ER stress inducer TM promoted bortezomib-induced apoptosis, leading to the suggestion that ER stress is directly involved in bortezomib-induced apoptosis.
Notably, bortezomib appears to induce apoptosis in PC cells through a mitochondrial apoptotic pathway, evidenced by the loss of Δψm, release of cytochrome c, as well as activation of caspase-9, caspase-3 and PARP. Bcl-2 family proteins regulate the mitochondrial apoptosis pathway by interacting with mitochondrial membranes to control the Δψm [39, 40] . Our data suggested that bortezomib dramatically decreased levels of the Bcl-2 family proteins Bcl-2, XIAP, and Bcl-XL. Similar to these results, bortezomib-mediated mitochondrial apoptosis was also observed in lung cancer cells [36] . Increasing intracellular calcium levels has been reported to play an important role in activating mitochondrial apoptosis due to mitochondrial calcium overload [35] . The accumulation of calcium into the mitochondria strictly depends on the ER, which serves as the primary organelle for calcium homeostasis [35] . In this study, confocal microscopy confirmed that bortezomib markedly increased mitochondrial calcium accumulation in PC cells, suggesting bortezomib-induced ER stress causes calcium to leak from the ER lumen into the mitochondria. Furthermore, BAPTA-AM pretreatment significantly inhibited bortezomib-induced Δψm loss and apoptosis, indicating that bortezomib- induced PC cell apoptosis may be mediated through increased levels of intracellular calcium. However, the Δψm stabilizer CsA only partially blocked bortezomib-induced apoptosis, suggesting that additional mechanisms are involved in this process.
Previous studies have reported that proteasome inhibitors induce autophagy in several cancer models [17, 29] . In accordance with these data, we found that bortezomib treatment of PC cells induced the accumulation of LC3B-II and autophagic vacuoles, promoted GFP-LC3B redistribution, and stimulated autophagic flux, all of which confirmed that autophagy was activated. Moreover, bortezomibinduced autophagy played a protective role in PC cells, as evidenced by the increased rate of bortezomib-induced apoptosis in autophagyinhibited cells. Beclin-1 is part of the class III phosphatidylinositol 3-kinase (PI3K) complex that is involved in autophagosome formation [14] . One particularly interesting observation is the discovery that Beclin1 knockdown had no obvious effects on bortezomib-induced apoptosis or autophagy, indicating that bortezomib induced autophagy in a Beclin1-independent manner. Similar to our findings, proteasome inhibitors have also been reported to cause Beclin1-independent autophagy in thyroid cancer cells [41] . Accumulating data indicate that ER stress is a potent trigger of autophagy [13, 32] . In these situations, autophagy counterbalances ER expansion, removes aggregated proteins, and thus, is cytoprotective. Indeed, pretreatment with the ER stress inhibitor TUDCA or transfecting CHOP-specific siRNA partially reduced bortezomib-induced LC3B-II accumulation, whereas the ER stress inducer TM promoted it. Additionally, inhibiting autophagy by Atg5 siRNA also increased bortezomib-induced ER stress-associated protein expression. Collectively, these findings strongly support the conclusion that ER stress precedes bortezomib-induced autophagy, which in turn ameliorates the ER stress.
Multiple lines of evidence have shown that, compared with their normal counterparts, cancer cells (including PC cells) seem to function with higher levels of intracellular ROS in culture and in vivo [18] . In fact, low ROS levels could promote the activities of several signaling proteins involved in cell proliferation and tumor progression through multiple mechanisms. However, if the ROS levels exceed a certain threshold, they may become cytotoxic [18, 19] . Previous studies have indicated that bortezomib may induce ROS generation as part of its mechanism of action [36, 37] . Likewise, our results showed that bortezomib increased ROS in PC cells, which may be a key mediator of bortezomib-induced apoptosis, as apoptosis was blocked by the ROS scavenger NAC.
Additionally, NAC pretreatment also attenuated the bortezomib-induced increase of intracellular calcium and the increased expression of Bip, CHOP and LC3B-II, suggesting ROS may play an important role in bortezomib-induced ER stress and autophagy in PC cells.
However, under persistent intrinsic oxidative stress, cancer cells become highly adapted to such ROS stress and develop a set of endogenous antioxidant capacities. These adaptive mechanisms not only activate ROS-scavenging systems to cope with the stress, but also make the malignant cells resistant to anticancer agents [18, 19] . Several studies have suggested that resistance anticancer agents that induce intracellular ROS production is correlated with increased antioxidant capacity [18, 19] . Recently, increasing evidence has supported the function of autophagy under metabolic stress as a way to remove damaged organelles and accumulated proteins, which lowers intracellular ROS levels [38] . Consistent with previous observations, we found that suppressing autophagy with CQ of Atg5 knockdown increased bortezomib-induced ROS levels, indicating that autophagy maybe involved in protecting PC cells against bortezomib-induced oxidative stress. Additionally, the Nrf2-mediated antioxidant response is critical for maintaining cellular redox homeostasis [23, 24] . In our experiments, levels of Nrf2 and its downstream targets were dramatically increased under bortezomib treatment, and silencing Nrf2 resulted in a further elevation of bortezomib-induced ROS as well as increased LC3B-II expression. These results indicated that when faced with oxidative stress, and the Nrf2 pathway is suppressed, autophagy is further promoted to deal with excessive ROS. Interestingly, Atg5 knockdown also led to increased bortezomib-induced Nrf2 expression. Thus, we hypothesized that there could be a negative interaction between autophagy and the Nrf2 pathway when cells were stimulated with high-level ROS, as both are required to coordinately deal with ROS-mediated damage and promote PC cell survival. Indeed, our next experiments proved that simultaneously suppressing autophagy and Nrf2 signaling cooperatively augmented bortezomibinduced ROS, which subsequently enhanced bortezomib-induced apoptosis, as NAC pretreatment significantly attenuated the apoptosis rates induced by the combination treatments. Similar to our findings, it was previously reported that ionizing radiation-induced ROS promoted autophagy and Nrf2, which conferred radio-resistance in lung cancer cell [42] .
In summary, this study suggests that autophagy and the Nrf2 antioxidant system, which both can lower intracellular ROS, are involved in the mechanism of bortezomib-resistance in PC cells. Combined with their negative interaction, we provide the basis for future preclinical and clinical trials exploring proteasome inhibitors and novel drug targets to co-inhibit autophagy and Nrf2 signaling as a combinatory therapeutic approach for PC.
Materials and Methods
Cell culture and reagents
Human pancreatic cancer cell lines MIAPaCa-2 and AsPC-1 were purchased from American Type Culture Collection (Manassas, VA, USA). All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) or Roswell Park Memorial Institute 1640 (RPMI-1640) medium supplemented with 10% fetal bovine serum (FBS), 2 mmol/l of glutamine, 100 units/ml of penicillin and 100 mg/ml of streptomycin in a 5% CO2 atmosphere at 37°C. Bortezomib and cyclosporin A (CsA) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Chloroquine (CQ), BAPTA-AM and N-acetyl-L-cysteine (NAC) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tauroursodeoxycholic acid (TUDCA) and tunicamycin (TM) were obtained from Calbiochem (Merck, Darmstadt, Germany). JC-1, Fluo-3/AM and 2', 7'-dichlorofluorescin diacetate (DCFH-DA) were obtained from Beyotime (Haimen, China). MitoTracker Red was obtained from Invitrogen (Carlsbad, CA, USA). All commercial antibodies were purchased from the following resources: anti-LC3B, anti-Beclin1, anti-Atg5, anti-Atg7, anti-Calnexin, anti-ubiquitin, anti-CHOP, anti-Bip, anti-p-JNK, anti-PARP, anti-cleaved caspase-3, anti-caspase-9 and anti-Lamin B1 antibodies were from Cell Signaling Technology (Beverly, MA, USA); anti-JNK antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-Nrf2, anti-HO-1, anti-NQO1, anti-Bcl-XL, anti-Bcl-2 and anti-cytochrome c antibodies were from Epitomics (Burlingame, CA, USA); anti-GAPDH antibody was from Proteintech Group (Chicago, IL, USA); anti-XIAP antibody and horseradish peroxidase-conjugated secondary antibodies (goat anti-rabbit and goat anti-mouse) were purchased from Beyotime (Haimen, China). The chemicals were dissolved in either appropriate media solution or dimethyl sulfoxide (DMSO) and then treated at the required working dilution. All chemicals were handled in accordance with the supplier's recommendations.
Cell viability assay
The cell viability was measured using CCK-8 assay (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Briefly, Cells (5,000 per well) were plated in 96-well plate. After 24 h, cells were treated with the chemical agents as indicated in the figure legends. DMSO was used as vehicle. After 10 μL WST-8 dye was add to each well, cells were incubated at 37°C with 5% CO2 for 2 h and the absorbance was finally measured at 450 nm with a microplate reader (Bio-tek Instruments, VT, USA).
Colony formation assay
To determine the long-term effects of drug treatment on cell colony formation, cells (500 cells) were seeded in a 6-well plate and treated as indicated in the figure legends. After rinsing with fresh medium, cells were incubated for 14 days and photographed after staining with 1% (w/v) crystal violet in phosphate-buffered saline (PBS) including 25% methanol. The number of colonies, defined as ≥ 50 cells/colony, was counted and compared with untreated cells.
Annexin V-FITC/propidium iodide (PI) apoptosis assay
Cell apoptosis was detected following specific treatments by staining using the 
Mitochondrial transmembrane potential assessment
Mitochondrial membrane potential (MMP, Δψm) was analyzed by a fluorescent dye JC-1. Briefly, after indicated treatments, cells were incubated with JC-1 staining solution (5 μg/mL) for 20 min at 37 °C. Cells were then rinsed twice with PBS and the fluorescence of separated cells was detected by FACS-Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
Protein isolation and western blot analysis
After treatment with different conditions as described in the figure legends, cells were harvested and lysed on ice in RIPA buffer (Beyotime, Haimen, China). After centrifuged at 12 000 g for 15 min, the clear supernatant was collected and used as the cell protein extract. For preparation of cytosolic and mitochondrial fractions, cells were collected and lysed in lysis buffer using mitochondria/cytosol fractionation kit (Beyotime, Haimen, China). Cytosol and mitochondrial extracts were isolated according to the manufacturer's protocol. Nuclear protein was extracted according to the manufacturer's instructions of the nuclear/cytoplasmic protein extraction kit (Beyotime, Haimen, China). Protein concentration was determined using the bicinchoninic acid protein assay kit (Beyotime, Haimen, China). Equivalent amounts of protein (30 μg) from each sample were subjected to electrophoresis on a SDS-polyacrylamide gel, and then transferred on to PVDF membranes (Millipore, Bedford, MA, USA). Target antigens were detected with primary antibodies and subsequently secondary antibodies. Immunoreactive bands were then developed using an ECL chemiluminescence reagent (Pierce, Rockford, IL, USA), according to the manufacturer's instruction. The density of each band was measured using the public domain NIH Image software (open source Image J software available at http://rsb.info.nih.gov/ij/).
Immunofluorescence and confocal laser-scanning microscopy
After transfection with GFP-LC3B or GFP-mRFP-LC3B, cells were grown on glass coverslips. Following designated treatments, the fluorescent autophagy marker GFP-LC3B or GFP-mRFP-LC3B were observed under a confocal microscope (OLYMPUS, FluoView FV1000). The average number of GFP-LC3B dots per cell was determined from 3 independent experiments. 10 random fields representing 200 cells were counted on each coverslide.
For immunofluorescence, cells were seeded on sterile cover glasses placed in the 6-well plates. After designated treatments, cells were fixed with 4% formaldehyde for 15 min followed by permeabilization with 0.1% (w/v) Triton X-100 for 10 min. Fixed cells were washed and blocked with 2% BSA for 30 min, then incubated with primary antibodies against Calnexin 4°C overnight. After washing twice with PBS, antibody was visualized with Cy3-conjugated secondary antibody. Subsequently, cells were counterstained with 6-diamino-2-phenylindole (DAPI, Sigma) and observed under a confocal microscope (OLYMPUS, FluoView FV1000).
To detect the localization of intracellular calcium and mitochondrion, cells were grown on glass coverslips. Following designated treatments, the cells were first stained with MitoTracker Red (50 nM) at 37°C for 30 min. After washing with Hanks' balanced salt solution (HBSS), the cells were loaded with Fluo-3/AM (3 μM) staining solution at 37°C for 1 h. Subsequently, the stained cells were immediately fixed with 4% paraformaldehyde for 10 min and observed under a confocal microscope (OLYMPUS, FluoView FV1000).
Transmission electron microscopy
After designated treatments, cells were first fixed in 3.0% glutaraldehyde, post-fixed with 1% osmium tetroxide for 1 h at 4°C, dehydrated by a graded series of ethanol (30%-100%), and then polymerized by epoxy resin. Ultra-thin sections were cut and stained with 4% uranyl acetate and lead citrate. Finally, ultra-structure of the cells was observed under a Tecnai G2 F20 S-TWIN transmission electron microscope (FEI).
Measurement of intracellular calcium
The intracellular calcium level was measured by using the fluorescent dye Fluo-3/AM. Briefly, after indicated treatments, the cells were collected and incubated with Fluo-3/AM (3 μM) staining solution at 37°C for 1 h. Then, the residual fluorescent dyes were washed with Hanks' balanced salt solution (HBSS) and the fluorescence of separated cells was detected by FACS-Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
Measurement of intracellular reactive oxygen species
Production of intracellular reactive oxygen species (ROS) was measured by using the fluorescent dye 2, 7-dichlorofluorescein diacetate (DCFH-DA) as a substrate. Briefly, after indicated treatments, cells were stained with 10 μM DCFH-DA in Hank's balanced salt solution (HBSS) for 30 min before collecting. For quantitative assessment of ROS generation, cells were collected, suspended in PBS and analyzed by FACS-Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). For image taking, DCFH-DA loaded cells were visualized using a fluorescent microscope (Olympus, Tokyo, Japan).
Transfection and RNA interference
The lentiviral vector containing GFP-LC3B and GFP-mRFP-LC3B reporter were constructed by GeneChem (Shanghai, China) and transfection was carried out according to the manufacturer's instructions. The double-stranded siRNA duplex for Atg5 (5'-GAAGUUUGUCCUUCUGCUA-3'), Nrf2 (5'-GTAAGAAGCCAGATGTTAA-3'), CHOP (5'-GC CUGGUAUGAGGACCUGC-3') and non-targeting scramble siRNA were synthesized chemically from Ribobio (Guangzhou, China) and resuspended in RNase-free buffer to a concentration of 20 μM. For siRNA transfection, cells were seeded into 6-well plates in antibiotic-free media and transfected at 30-50% confluency with 50 nM siRNA in Opti-MEM (Invitrogen) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Statistical analysis
Data are presented as the mean ± SD from at least three separate experiments unless otherwise indicated. Levels of significance were evaluated by 2-tailed Student's t-test using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA). A difference was considered statistically significant when P < 0.05.
